Published in final edited form as:

Otol Neurotol. 2018 October ; 39(9): 1122–1128. doi:10.1097/MAO.0000000000001951.

Evaluation of outcome variability associated with lateral wall, mid-scalar, and perimodiolar electrode arrays when controlling for pre-operative patient characteristics

Joshua E. Fabie, BS, Robert G. Keller, MD, Jonathan L. Hatch, MD, Meredith A. Holcomb, AuD, Elizabeth L. Camposeo, AuD, Paul R. Lambert, MD, Ted A. Meyer, MD, and Theodore R. McRackan, MD, MSCR

Department of Otolaryngology – Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA

Abstract

Objective—Determine the impact of electrode array selection on audiometric performance when controlling for baseline patient characteristics.

Study Design—Retrospective evaluation of a prospective cochlear implant (CI) database (1/1/12–5/31/17).

Setting—Tertiary Care University Hospital

Patients—328 adult CI recipients

Interventions/Main Outcomes Measured—Hearing outcomes were measured through unaided/aided pure tone thresholds and speech recognition testing before and after cochlear implantation. All reported post-operative results were performed at least 6 months after CI activation. All device manufacturers were represented.

Results—Of the 328 patients, 234 received lateral wall (LW) arrays, 46 received perimodiolar (PM) arrays, and 48 received mid-scalar (MS) arrays. Patients receiving PM arrays had significantly poorer pre-operative earphone and aided PTAs and SRTs, and aided CNC word and AzBio +10 SNR scores compared to patients receiving LW arrays (all $p < 0.04$), and poorer PTAs and AzBio +10 SNR scores compared to MS recipients (all $p < 0.02$). No pre-operative audiological variables were found to significantly differ between MS and LW patients. After controlling for pre-operative residual hearing and speech recognition ability in a hierarchical multiple regression analysis, no statistically significant difference in audiological outcomes was detected (CNC words, AzBio quiet, or AzBio +10 SNR) among the three electrode array types (all $p > 0.05$).

Correspondence may be sent to: Theodore McRackan, Mailing Address:, Medical University of South Carolina, 135 Rutledge Avenue, MSC 550, Charleston, SC, USA 29425-5500, mcrackan@musc.edu, Phone: (843) 876-5019, Fax: (843) 792-5910.

Conflict of Interest Disclosures:

Dr. Holcomb is on the medical advisory board for and has received personal fees from Advanced Bionics and Cochlear Americas and has received grants from Med El Corporation. Dr. Meyer is on the medical advisory board for Advanced Bionics. Dr. Lambert is on the medical advisory board for Cochlear Americas. No other disclosures are reported.

Conclusion—While prior studies have demonstrated superior post-operative speech recognition scores in LW electrode array recipients, these differences lose significance when controlling for baseline hearing and speech recognition ability. These data demonstrate the proclivity for implanting individuals with greater residual hearing with LW electrodes and its impact on post-operative results.

Keywords

cochlear implant; hearing; sensorineural hearing loss

INTRODUCTION

Adult cochlear implant (CI) outcomes are known to be impacted by a number of factors including postlingual onset of deafness, age at implantation, duration of hearing loss, hearing aid use, and pre-operative hearing level.^{1–6} Beyond patient specific factors that cannot be altered, differences in devices and their placement represent a potential source of post-operative outcome variability.^{7,8} Improvement in CI outcomes over time has been synchronous with refinement of surgical techniques and implant technology. Electrode design, intrascalar positioning, and atraumatic operative techniques are thought to be significant predictors of post-op speech recognition ability.^{5–7,9–14} Electrode array selection is one of the few modifiable aspects of CI surgery; however, the impact of this choice in relation to patient specific factors is an ongoing area of investigation.

Electrode arrays are ideally placed within the scala tympani (ST) and classified according to intrascalar position as either perimodiolar (PM), mid-scalar (MS), or lateral wall (LW). MS electrodes target an intermediate trajectory within the ST but are often considered a PM subcategory.¹⁵ Electrodes achieving a final position closer to spiral ganglion cells within Rosenthal's canal are thought to reduce compound action potential thresholds and cross channel interaction, transferring high definition electrical signal directly to neurons.^{16,17} When electrodes reside entirely within the ST, these features of PM arrays have been associated with increased word recognition ability.^{5,14} However, precurved arrays designed to hug the modiolar wall also have a higher incidence of intracochlear trauma, often due to scalar excursion into the scala vestibuli (SV).^{13,14,18–21}

Reducing damage to intracochlear architecture is an area of increased focus due to implanting patients with a greater degree of residual hearing. Preserved low-frequency perception at the cochlear apex is the goal of such surgery, which allows electrical and acoustic stimulation resulting in superior speech understanding.^{17,22,23} Maintenance of functional hearing after surgery is more likely with the insertion of LW electrodes, which less commonly deviate from the ST.^{19–21} Thus, patients under consideration for CI may be separated into two categories: those with very poor hearing requiring optimal electrical stimulation, and those who may benefit from preserved residual hearing combined with electrical stimulation.

While superior post-operative CI speech recognition scores have been observed in patients utilizing a LW electrode,²⁰ baseline patient characteristics likely influence pre-operative therapeutic decisions, and accordingly, post-operative outcomes. We hypothesized that pre-

operative patient factors impact performance after implantation to a greater degree than electrode selection. The primary aim of this study was to determine if post-operative hearing scores vary between lateral wall, mid-scalar, and perimodiolar electrode array recipients after controlling for baseline hearing status.

MATERIALS AND METHODS

The study was approved by the Medical University of South Carolina IRB - Pro00071518 and consisted of adult CI patients from a single tertiary care institution. The Medical University of South Carolina Cochlear Implant Program maintains a prospective database for all of its CI patients. The current study is a retrospective analysis of adults with post-lingual hearing loss who underwent cochlear implantation from Jan. 2012 to May 2017. Exclusion criteria included: patients who underwent their initial CI surgery elsewhere thus pre-operative data were not available, patients with incomplete audiometric data; patients who had revision CI surgery; and patients without a minimum of 6 months post-activation follow up speech recognition data. Patients were categorized by CI device and array style (LW, PM, or MS). All three current US-FDA approved implant manufacturers were represented. Choice of CI manufacturer was determined by the patient unless a medical reason existed to recommend one company over the others.

Demographic data including age, gender, ethnicity, insurer, pre-operative hearing aid use, and duration of hearing loss were collected for patients meeting study criteria. Baseline hearing ability was assessed by pure-tone average (PTA), speech recognition thresholds (SRT), and Consonant-Nucleus-Consonant word scores (CNC) tested under earphone (supra-aural headphone or inserts) and aided conditions, and AzBio sentence scores in quiet and noise (multi-talker babble; +10dB SNR) tested under aided conditions. Follow up speech recognition ability was tested using CNC, AzBio quiet, and AzBio +10 SNR (AzBio +10). For both aided and implanted conditions, AzBio +10 was used when individuals scored >50% on AzBio quiet. Reported pure-tone averages were calculated using the average air conduction thresholds at 500, 1000, and 2000 Hz.^{24,25} Earphone CNC scores were obtained at uncomfortable loudness level (determine with speech signal) minus 5 dB SPL for all patients. Aided and implanted speech recognition testing was performed with speech presented at 60 dB SPL in the sound field in a sound treated room. Hearing aid users were tested with their personal hearing aids, while non-hearing aid users were provided stock hearing aids for testing. All hearing aids (personal and stock) were programmed to meet The National Acoustic Laboratories' Non-Linear (NAL-NL) target thresholds prior to testing.

Statistical Analysis

Simple descriptive statistics such as frequency, percentage, mean, standard deviation, standard error, minimum, and maximum were calculated for all outcome variables. Statistical analyses of baseline demographic and audiologic data were performed using Chi-square test or Fisher's test for nominal variables and a One-Way Analysis of Variance followed by a Tukey posthoc comparison test, if needed, for continuous variables. Pre- to post-operative differences in CNC, AzBio quiet, and AzBio +10 scores within each

electrode group were assessed using paired T-tests, and speech recognition differences between electrode array groups at pre- and post-operative time points were analyzed by ANOVA. A One-Way Analysis of Covariance (ANCOVA) was conducted for each of the three tests of speech recognition to determine any statistically significant differences in post-operative speech recognition between electrode styles after controlling for baseline hearing status. Corresponding pre-operative scores were used as covariates in order to determine estimated marginal means adjusted for baseline speech recognition and reveal the percent of variance in outcomes attributable to baseline hearing status.

Hierarchical multiple regression—Following a review of relevant assumptions for statistical analysis, hierarchical multiple linear regression was conducted to determine whether electrode selection explained unique variance in post-operative speech recognition after controlling for baseline hearing status. Hierarchical regression determines whether independent variables of interest predict the dependent variable above and beyond the effect of pre-existing factors. Separate ordinary least squares regression models are built in each step and compared to determine if the successive model's fit is superior to the first. Post-operative CNC, AzBio quiet, or AzBio +10 scores were used as the dependent variable, and electrode type and pre-operative audiometric variables found to correlate with post-operative CNC, AzBio quiet, or AzBio +10 were used as independent variables. A two-stage hierarchical linear regression was performed for each post-operative test of speech recognition. Because hearing status necessarily preceded CI consideration and its potential influence on electrode selection, pre-operative speech recognition was entered as the first step in the regression equation and electrode category was entered as the second step.

Pre-op aided CNC and AzBio quiet were correlated with an r value of 0.813. Correlations between other independent variables met the assumption of singularity (all $r < 0.7$), and collinearity statistics (i.e., tolerance and variance inflation factor) for all variables were all within limits to meet the assumption of multicollinearity. 5 multivariate outliers in the regressions for post-operative CNC and 6 outliers in the regression for AzBio quiet were identified based on Mahalanobis distance scores which were removed from the data set. Assumptions of normality, linearity, and homoscedasticity were assessed via residual and scatter plots and found to be satisfied. Missing values were excluded pairwise. In order to maintain a subject-to-variable ratio 15:1, pre-operative AzBio +10 scores were excluded from regressions. A p value of <0.05 was considered to indicate a statistically significant difference for all statistical tests. All statistical analysis was performed using SPSS version 24.0 (IBM Corp., Armonk, NY), SigmaPlot 12.5 (Systat Software, San Jose, CA), and MedCalc 17.9.7 (MedCalc Software, Oostende, Belgium).

RESULTS

328 CI recipients met inclusion criteria. Patients were 55.5% male, and the average age at implantation was 63.7 ± 16.7 years (range, 19–94 years). The mean duration of hearing loss prior to implantation was 24.2 ± 17.2 years, and 64.9% of patients utilized a hearing aid on the implanted side pre-operatively. 234 (71.3%) received LW arrays, 46 (14.0%) received PM arrays, and 48 (14.6%) received MS arrays. Age, gender, ethnicity, insurance, pre-

operative hearing aid use, and duration of hearing loss did not significantly differ between electrode array groups (Table 1).

Pre-operative performance—Tables 2 and 3 display demographic and audiologic data based on electrode array group. Overall, patients in the PM group had worse pre-operative hearing than the LW group. The PM group had higher mean earphone and unaided PTAs and SRTs and lower aided CNC and AzBio +10 scores (all $p < 0.036$). Although MS and PM electrodes were both selected for patients with worse hearing, MS recipients' aided and earphone PTA and AzBio +10 scores were significantly better than those of PM patients (all $p < 0.024$). Pre-operative hearing status did not significantly differ between MS and LW recipients.

Post-operative performance—Post-operative CNC, AzBio quiet, and AzBio +10 scores were significantly improved from baseline following implantation in all electrode groups (all $p < 0.001$). LW array recipients' post-operative CNC, AzBio quiet, and AzBio +10 scores compared favorably to patients implanted with PM or MS electrodes. However, only the improved AzBio +10 scores of LW patients over those implanted with MS arrays reached significance ($p = 0.007$). When post-operative mean scores were adjusted for covariance in baseline speech recognition ability in the ANCOVA to calculate estimated marginal means, no significant differences in post-operative performance were detected between electrode types (all $P > 0.074$). Adjustment for pre-operative covariance yielded higher scores for PM patients and lower scores for LW and MS patients compared to actual post-operative performance. This indicates that by accounting for pre-operative hearing status, the mean differences in CNC, AzBio quiet, and AzBio +10 scores between LW and PM recipients fell from 4.5% to 2.6%, 1.3% to 0.0%, and 13.9% to 2.4%, respectively. Despite poorer pre-operative performance, PM recipients outperformed MS patients after implantation, and comparison of estimated marginal means further expounded the relatively larger performance gain with PM arrays (Table 3). Speech recognition results were not found to significantly differ on the basis of CI manufacturer (Table 4).

Hierarchical multiple regression—We hypothesized that post-operative speech recognition testing would positively correlate with pre-operative CNC, AzBio quiet, and AzBio +10 scores, and negatively correlate with PTA and SRT in both aided and earphone conditions. In order to build our multiple regression models, univariate correlations were first performed (Table 5). Pre-operative audiologic data showed the strongest correlation with post-operative AzBio +10 scores. Aided CNC and AzBio +10 scores positively correlated with post-operative AzBio +10 scores. As expected, aided PTA and SRT negatively correlated with post-operative AzBio +10 scores.

Due to the clear electrode design difference between LW and PM arrays, these groups were selected to compare in the hierarchical multiple regression. Correlated pre-operative scores from table 5 were entered as the first step, and whether the patient received a LW or PM array was entered as the second step in the hierarchical equations for post-operative speech recognition. This two-step design explored whether array selection impacted post-operative speech recognition after controlling for baseline hearing performance. Hierarchical multiple

linear regression of pre- and post-operative speech recognition for LW and PM recipients revealed, pre-operative performance contributed significantly to the regression model for all three measures of post-operative speech recognition, accounting for 9.7%, 9.2%, and 14.1% of the variation in post-operative CNC, AzBio quiet, and AzBio +10 scores, respectively (all $p < 0.035$). When controlled for pre-operative performance, electrode selection was not found to significantly impact any post-operative measures of speech recognition (Table 6).

DISCUSSION

Given the propensity at our institution and others to implant patients with greater residual hearing with LW electrodes versus PM or MS arrays, we expected to find significant pre-operative hearing differences among these groups. Our analysis revealed significant differences in pre-operative hearing status between LW and PM groups. LW patients had significantly better PTAs and SRTs than PM patients and significantly outperformed PM patients on CNC and AzBio +10 testing pre-operatively (Table 2). The overall superior hearing pre-operatively noted in the LW group compared to the PM and MS groups, again, was not surprising given the tendency at our institution to choose a LW array for patients with greater residual hearing. Our data are consistent with at least two other studies comparing LW and PM array performance, where the authors similarly noted better pre-operative hearing in the LW groups.^{20,26}

The greater pliability of the LW implant than the more rigid, pre-curved PM array is thought to make it less likely to translocate into the SV, thereby avoiding damage to the basilar membrane, Reissner's membrane and organ of Corti, and increasing the likelihood of preserving residual hearing.^{19,26,27} Given the increased likelihood of hearing preservation with a LW electrode, at our institution and others, there has traditionally been a tendency toward choosing a LW electrode over a PM array in those patients with more intact pre-operative hearing levels. Conversely, in patients who retain little to no residual hearing pre-operatively, a PM electrode is chosen with its pre-curved design providing the hypothetical advantage of greater electrode apposition to the spiral ganglion neurons, less energy usage, and greater overall speech understanding. Acknowledging LW electrodes are typically chosen for patients with greater pre-operative hearing and post-operative CI performance correlates with pre-operative hearing status, it is therefore tenable that LW electrodes would be expected to have improved post-operative hearing outcomes. It was our intent to determine if this expectation is valid when pre-operative hearing status is considered.

We did not find any significant differences in post-operative performance based on electrode type. However, we did find that pre-operative hearing status had a greater impact on post-operative outcomes than electrode array selection. Prior studies have reported inconsistent hearing outcomes for recipients of differing arrays. Some have been in agreement with the results of the present study, reporting no significant differences among the electrode styles,^{28–30} while others have supported a hearing advantage with either the PM³¹ or LW²⁰ electrode. The recent study by O'Connell et al. found significantly higher CNC and AzBio scores in LW compared to PM arrays, which was attributed to lower rates of implant extrusion into the SV for the LW cohort.²⁰ A significant limitation to our study, and most studies evaluating CI outcomes, is the lack of knowledge of electrode location within the

cochlea and the rates of array extrusion from the ST into the SV. Unfortunately, this technology is not routinely available for clinical use and there is no clinical intervention for patients where array extrusion is seen. A number of studies have previously shown that LW electrodes are more likely to solely reside in the ST than other array designs. This is presumed to result in better performance as electrodes residing entirely in the ST correlate with better hearing outcomes.^{14,28} Wana et. al compared outcomes between LW and PM electrodes and found more LW electrodes (89%) resided completely within the ST than their PM counterparts (58%), and that electrodes residing solely within the ST had better post-operative mean CNC-word performance (48.9%) than those located outside the ST (36.1%).¹⁴ Additional work by this group, compared electrode types (LW, PM, MS), their likelihood to reside within the ST, and associated hearing performance.²⁸ This revealed that PM and MS arrays were 22 and 55 times more likely to have electrodes residing outside of the ST than LW arrays, respectively. Furthermore, SV insertion was associated with a 12% decrease in CNC score. However, consistent with our findings, when simply evaluating outcomes based on electrode array type, irrespective of electrode location, there were no significant differences in CNC scores found.²⁸ Therefore, it is possible that LW electrodes do have a positive impact on CI outcomes, but only when inserted entirely within the ST. However, further data are required to evaluate the influence of individual pre-operative audiologic data on this statement.

While the impact of electrode array selection on audiometric performance has been assessed in prior articles, and some evidence has suggested a performance benefit in patients with lateral wall electrodes due to less frequent translocations out of the ST, previous studies do not adequately control for baseline hearing. The present study represents the first time the outcomes of a very large population of CI recipients from all three FDA approved implant manufacturers have been controlled for pre-operative hearing status in a modern statistical manner.

Despite similar post-operative hearing outcomes between our LW and PM groups, we performed a hierarchical multiple regression analysis of pre- and post-operative speech recognition for LW and PM implantees to identify the contribution of the observed pre-operative hearing differences on the post-operative audiometric results. Confirming our hypothesis, the regression analysis revealed that pre-operative differences had a significant impact on post-operative hearing scores. We noted that pre-operative aided CNC, AzBio quiet, and AzBio +10 scores contributed significantly to the regression model, accounting for 9.7%, 9.2%, and 14.1% of the variation in post-operative CNC, AzBio quiet, and AzBio +10 scores, respectively. Again, when controlled for pre-operative performance, electrode selection was not found to significantly impact any post-operative measures of speech recognition.

There were a number of limitations to our study. The study was performed in a retrospective fashion which is suboptimal for comparative studies and introduces the potential for bias. Patients in this study were treated by four different surgeons, all with subtle differences or nuances of surgical techniques and approaches to hearing preservation during cochlear implantation. Although diversity in technique/device choice allows greater generalizability, all patients were also treated at a single institution, which may limit the applicability of our

results to implant programs with distinctly different tendencies in the use of each electrode type. As previously mentioned, imaging data to confirm electrode placement were not available for comparison; however, the rate of electrode transgression into the SV in the study population would not be expected to significantly differ from prior research.

CONCLUSION

The optimal cochlear implant array design that confers the greatest hearing benefit to patients has yet to be fully clarified. Growing evidence supports arrays residing solely within the ST as likely outperforming those that have translocated into the SV, and both cadaveric and in-vivo electrode localization studies have now shown LW arrays being most likely to remain in the ST. Prior to accepting LW arrays as being the most favorable design, however, it is prudent to directly correlate improved hearing outcomes with these arrays over their counterparts. Our study underscores the proclivity for implanting better hearing patients with LW arrays and the impact this selection bias has on comparative hearing outcomes analysis between LW and PM or MS implantees. Moving forward, it is imperative for future studies comparing hearing performance between array designs to consider underlying pre-operative auditory discrepancies among these groups. Further investigation will continue to be crucial in bettering our understanding of how array design and intracochlear electrode location may render improved hearing outcomes after implantation.

Acknowledgments

This publication was supported by a K12 award through the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NIH/NCATS Grant Number UL1TR001450, and a grant from the Doris Duke Foundation.

References

1. Tong YC, Busby PA, Clark GM. Perceptual studies on cochlear implant patients with early onset of profound hearing impairment prior to normal development of auditory, speech, and language skills. *J Acoust Soc Am*. 1988; 84:951–62. [PubMed: 3183213]
2. Rubinstein JT, Parkinson WS, Tyler RS, et al. Residual speech recognition and cochlear implant performance: effects of implantation criteria. *Am J Otol*. 1999; 20:445–52. [PubMed: 10431885]
3. Lazard DS, Vincent C, Venail F, et al. Pre-, per- and postoperative factors affecting performance of postlinguistically deaf adults using cochlear implants: a new conceptual model over time. *PLoS One*. 2012; 7:e48739. [PubMed: 23152797]
4. Blamey P, Artieres F, Baskent D, et al. Factors affecting auditory performance of postlinguistically deaf adults using cochlear implants: an update with 2251 patients. *Audiol Neurotol*. 2013; 18:36–47. [PubMed: 23095305]
5. Holden LK, Finley CC, Firszt JB, et al. Factors affecting open-set word recognition in adults with cochlear implants. *Ear Hear*. 2013; 34:342–60. [PubMed: 23348845]
6. Holden LK, Firszt JB, Reeder RM, et al. Factors Affecting Outcomes in Cochlear Implant Recipients Implanted With a Perimodiolar Electrode Array Located in Scala Tympani. *Otol Neurotol*. 2016; 37:1662–68. [PubMed: 27755365]
7. Finley CC, Holden TA, Holden LK, et al. Role of electrode placement as a contributor to variability in cochlear implant outcomes. *Otol Neurotol*. 2008; 29:920–8. [PubMed: 18667935]
8. Wanna GB, Noble JH, McRackan TR, et al. Assessment of electrode placement and audiological outcomes in bilateral cochlear implantation. *Otol Neurotol*. 2011; 32:428–32. [PubMed: 21283037]
9. Aschendorff A, Kromeier J, Klenzner T, et al. Quality control after insertion of the nucleus contour and contour advance electrode in adults. *Ear Hear*. 2007; 28:75S–79S. [PubMed: 17496653]

10. Carlson ML, Driscoll CL, Gifford RH, et al. Implications of minimizing trauma during conventional cochlear implantation. *Otol Neurotol.* 2011; 32:962–8. [PubMed: 21659922]
11. Gifford RH, Dorman MF, Skarzynski H, et al. Cochlear implantation with hearing preservation yields significant benefit for speech recognition in complex listening environments. *Ear Hear.* 2013; 34:413–25. [PubMed: 23446225]
12. Skinner MW, Holden TA, Whiting BR, et al. In vivo estimates of the position of advanced bionics electrode arrays in the human cochlea. *Ann Otol Rhinol Laryngol Suppl.* 2007; 197:2–24. [PubMed: 17542465]
13. Sweeney AD, Hunter JB, Carlson ML, et al. Durability of Hearing Preservation after Cochlear Implantation with Conventional-Length Electrodes and Scala Tympani Insertion. *Otolaryngol Head Neck Surg.* 2016; 154:907–13. [PubMed: 26908553]
14. Wana GB, Noble JH, Carlson ML, et al. Impact of electrode design and surgical approach on scalar location and cochlear implant outcomes. *Laryngoscope.* 2014; 124(Suppl 6):S1–7.
15. Dhanasingh A, Jolly C. An overview of cochlear implant electrode array designs. *Hear Res.* 2017; 356:93–103. [PubMed: 29102129]
16. Cohen LT. Practical model description of peripheral neural excitation in cochlear implant recipients: 2. Spread of the effective stimulation field (ESF), from ECAP and FEA. *Hear Res.* 2009; 247:100–11. [PubMed: 19063955]
17. van Wermeskerken GK, van Olphen AF, Graamans K. Imaging of electrode position in relation to electrode functioning after cochlear implantation. *Eur Arch Otorhinolaryngol.* 2009; 266:1527–31. [PubMed: 19308437]
18. Wana GB, O'Connell BP, Francis DO, et al. Predictive factors for short- and long-term hearing preservation in cochlear implantation with conventional-length electrodes. *Laryngoscope.* 2017
19. Wana GB, Noble JH, Gifford RH, et al. Impact of Intrascalar Electrode Location, Electrode Type, and Angular Insertion Depth on Residual Hearing in Cochlear Implant Patients: Preliminary Results. *Otol Neurotol.* 2015; 36:1343–8. [PubMed: 26176556]
20. O'Connell BP, Hunter JB, Gifford RH, et al. Electrode Location and Audiologic Performance After Cochlear Implantation: A Comparative Study Between Nucleus CI422 and CI512 Electrode Arrays. *Otol Neurotol.* 2016; 37:1032–5. [PubMed: 27525618]
21. Boyer E, Karkas A, Attye A, et al. Scalar localization by cone-beam computed tomography of cochlear implant carriers: a comparative study between straight and perimodiolar precurved electrode arrays. *Otol Neurotol.* 2015; 36:422–9. [PubMed: 25575374]
22. Gantz BJ, Dunn C, Oleson J, et al. Multicenter clinical trial of the Nucleus Hybrid S8 cochlear implant: Final outcomes. *Laryngoscope.* 2016; 126:962–73. [PubMed: 26756395]
23. Pillsbury HC, Dillon MT, Buchman CA, et al. Multicenter US Clinical Trial With an Electric-Acoustic Stimulation (EAS) System in Adults: Final Outcomes. *Otol Neurotol.* 2018; 39:299–305. [PubMed: 29342054]
24. Schapira AHV, Byrne E. *Neurology and clinical neuroscience.* Philadelphia: Mosby Elsevier; 2007. xxvi1626
25. Campbell K. *Essential audiology for physicians.* San Diego: Singular Pub. Group; 1998. viii191
26. Mady LJ, Sukato DC, Fruit J, et al. Hearing Preservation: Does Electrode Choice Matter? *Otolaryngol Head Neck Surg.* 2017; 157:837–47. [PubMed: 28608735]
27. O'Connell BP, Hunter JB, Wana GB. The importance of electrode location in cochlear implantation. *Laryngoscope Investig Otolaryngol.* 2016; 1:169–74.
28. O'Connell BP, Cakir A, Hunter JB, et al. Electrode Location and Angular Insertion Depth Are Predictors of Audiologic Outcomes in Cochlear Implantation. *Otol Neurotol.* 2016; 37:1016–23. [PubMed: 27348391]
29. Fitzgerald MB, Shapiro WH, McDonald PD, et al. The effect of perimodiolar placement on speech perception and frequency discrimination by cochlear implant users. *Acta Otolaryngol.* 2007; 127:378–83. [PubMed: 17453457]
30. Doshi J, Johnson P, Mawman D, et al. Straight versus modiolar hugging electrodes: does one perform better than the other? *Otol Neurotol.* 2015; 36:223–7. [PubMed: 25415467]

31. Park LR, Teagle HFB, Brown KD, et al. Audiological Outcomes and Map Characteristics in Children With Perimodiolar and Slim Straight Array Cochlear Implants in Opposite Ears. *Otol Neurotol*. 2017; 38:e320–e26. [PubMed: 28902802]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 1

Summary of patient characteristics

Variable	All	Lateral Wall	Perimodiolar	Mid-scalar	p-value
Number	328	234	46	48	
Age (mean±SD range)	63.7±16.7 (19–94)	64.2±16.1 (19–91)	61.1±17.6 (23–90)	64.1±18.6 (18–94)	0.50
Gender					
Male	182 (55.5%)	128 (54.7%)	23 (50.0%)	31 (64.6%)	0.33
Female	146 (44.5%)	106 (45.3%)	23 (50.0%)	17 (35.4%)	
Race					
White	278 (84.8%)	198 (84.6%)	38 (82.6%)	42 (87.5%)	0.55
African American	48 (14.6%)	35 (15.0%)	8 (17.4%)	5 (10.4%)	
Asian	2 (0.6%)	1 (0.4%)	0	1 (2.1%)	
Hearing aid use					
Yes	213 (64.9%)	159 (67.9%)	27 (58.7%)	27 (56.3%)	0.17
No	110 (33.5%)	70 (29.9%)	19 (41.3%)	21 (43.8%)	
Unknown	5 (1.5%)	5 (3.1%)	0	0	
Duration of hearing loss	24.2±17.2	24.5±17.1	23.8±16.5	23.1±18.4	0.87
Insurance					
Medicare	204	145	27	32	0.56
Medicaid	18	14	2	2	
Private	91	66	14	11	
Tricare	6	3	3	0	
Vocal Rehab	4	3	0	1	
Work Comp	3	3	0	0	

TABLE 2

One-way analysis of variance (ANOVA) of baseline hearing

	Variable	All	Lateral Wall	Perimodiolar	Mid-scalar	F	p-value ⁺⁺
Unaided (mean ±SD)	PTA	87.6±18.7	86.7±18.3	96.3±19.4	83.5±18.2	6.574	<0.00 1 0.004 2 0.517 3 0.003
	SRT	75.0±17.2	73.7±18.1	81.2±14.1	76.4±14.1	3.278	0.04 1 0.036 2 0.580 3 0.411
	CNC	12.9±17.8	13.3±17.7	8.3±16.7	15.3±18.4	2.020	0.13
Aided (mean ±SD)	PTA	45.2±18.5	43.1±16.3	54.5±24.6	46.1±19.9	7.063	<0.00 1 0.001 2 0.594 3 0.001
	SRT	41.5±12.0	39.9±10.4	47.0±16.0	44.5±13.4	7.464	<0.00 1 0.002 2 0.052 3 0.612
	CNC	7.2±11.5	8.0±12.1	2.8±5.9	7.8±11.7	4.020	0.02 1 0.014 2 0.994 3 0.088
	AzBio Quiet	9.8±14.8	10.4±14.8	5.0±10.3	11.9±18.2	2.792	0.06
	AzBio +10	14.8±15.6	18.4±16.4	0.1±0.3	16.1±11.8	7.268	<0.00 1 0.001 2 0.872 3 0.024

LW, lateral wall; PM, perimodiolar; MS, mid-scalar; PTA, pure-tone average; SRT, speech recognition threshold; CNC, consonant-nucleus-consonant word recognition; AzBio, sentence recognition in quiet; AzBio +10, sentence recognition in noise.

⁺⁺ Comparison 1 = LW x PM, 2 = LW x MS, and 3 = PM x MS

TABLE 3
One-way analysis of variance (ANOVA) and covariance (ANCOVA) of post-operative hearing

Variable	All	Lateral Wall	Perimodiolar	Mid-scalar	F	p-value ⁺⁺	Effect Size
CNC	40.5±20.8	41.8±21.1	37.3±19.2	37.7±20.7	1.524	0.219	0.009
ANCOVA		<u>41.5</u> emm	<u>38.9</u> emm	<u>37.4</u> emm	0.950	0.388	0.006
AzBio Quiet	54.5±27.3	55.6±27.4	54.3±29.7	49.2±24.0	2.170	0.116	0.013
ANCOVA		<u>55.5</u> emm	<u>55.5</u> emm	<u>48.7</u> emm	1.079	0.341	0.008
AzBio +10	49.8±23.4	55.3±23.0	41.4±22.9	35.4±19.1	5.279	0.007 ¹ 0.219 ² 0.007 ³ 0.528	0.095
ANCOVA		<u>53.6</u> emm	<u>51.2</u> emm	<u>32.6</u> emm	2.780	0.074	0.125

CNC, consonant-nucleus-consonant word recognition; AzBio, sentence recognition in quiet; AzBio +10, sentence recognition in noise; emm, estimated marginal mean.

⁺⁺ Comparison 1 = LW x PM, 2 = LW x MS, and 3 = PM x MS

TABLE 4

Post-operative scores by CI manufacturer

Variable	MED-EL	Advance Bionics	Cochlear Americas	F	p-value
CNC	(103) 37.9±18.7	(55) 38.4±21.2	(167) 43.2±21.8	2.498	0.084
AzBio Quiet	(102) 54.9±26.1	(56) 51.3±25.6	(165) 59.9±28.2	2.520	0.082
AzBio +10	(22) 42.0±22.7	(24) 35.4±20.9	(58) 47.6±21.2	2.796	0.066

CNC, consonant-nucleus-consonant word recognition; AzBio, sentence recognition in quiet; AzBio +10, sentence recognition in noise.

TABLE 5

Correlation of pre- and post-operative hearing performance

Pre-op Variable		Post-op CNC			Post-op AzBio Quiet			Post-op AzBio +10		
		N	Pearson R	p-value	N	Pearson R	p-value	N	Pearson R	p-value
Unaided (mean $\pm$ SD)	PTA	324	-0.138	0.013	322	-0.144	0.010	104	-0.106	0.282
	SRT	295	-0.100	0.087	294	-0.152	0.009	97	-0.221	0.030
	CNC	316	0.216	0.000	316	0.179	0.001	101	0.029	0.776
Aided (mean $\pm$ SD)	PTA	316	-0.175	0.002	315	-0.167	0.003	102	-0.265	0.007
	SRT	282	-0.176	0.003	284	-0.143	0.016	93	-0.227	0.029
	CNC	323	0.199	0.000	322	0.175	0.002	103	0.279	0.004
	AzBio Quiet	287	0.114	0.054	285	0.131	0.027	74	0.080	0.501
	AzBio +10	63	0.291	0.021	64	0.196	0.120	43	0.365	0.016

PTA, pure-tone average; SRT, speech recognition threshold; CNC, consonant-nucleus-consonant word recognition; AzBio, sentence recognition in quiet; AzBio +10, sentence recognition in noise.

TABLE 6

Hierarchical multiple regression of baseline hearing performance and electrode type

Variable	Step ⁺⁺	R Square	R Square Change	F Change	df1	df2	Sig. F Change
CNC	Step 1	0.097	0.097	3.651	6	201	0.002
	Step 2	0.098	0.001	0.039	1	200	0.843
AzBio Quiet	Step 1	0.092	0.092	2.485	8	197	0.014
	Step 2	0.093	0.001	0.296	1	196	0.587
AzBio +10	Step 1	0.141	0.141	2.538	5	77	0.035
	Step 2	0.149	0.007	0.651	1	76	0.422

CNC, consonant-nucleus-consonant word recognition; AzBio, sentence recognition in quiet; AzBio +10, sentence recognition in noise.

⁺⁺Step 1 = correlated speech recognition tests (excluding AzBio +10) and Step 2 = array selection